90-Second Read: Inflammatix Collaborates with University of Nebraska Medical Center to Support Rapid Response to the Hantavirus Outbreak Using TriVerity

Hantavirus presents a significant clinical challenge, often beginning with non-specific symptoms that resemble common viral illnesses but can rapidly progress to severe respiratory failure. TriVerity® incorporates a panel of 29 patient messenger RNAs (mRNAs) to rapidly interpret the body's immune response to infection using machine learning-derived algorithms. Government Support Acknowledgment TriVerity® was developed in part with funding from the U.S. Department of Health and Human Services; Biomedical Advanced Research and Development Authority (BARDA), under contracts 75A50119C00034, 75A50119C00044, and 75A50122C00069.

Host-response enables rapid assessment of infection type and risk of deterioration in high-consequence infectious disease setting. However, as with many viruses with pandemic potential, tests that specifically detect Hantaviruses are either not widely distributed (serology tests) or still under development (such as PCR tests). TriVerity® was developed based on research conducted at Stanford University by co-founders Tim Sweeney, MD, PhD, and Purvesh Khatri, PhD.

Inflammatix, Inc., based in Sunnyvale, California, USA, is redefining molecular diagnostics by leveraging machine learning and host-response biology to generate accurate, actionable results. Backed by leading healthcare investors and federal support, the company aims to improve outcomes and lower costs through faster, smarter testing. Early identification of patients at risk of deterioration remains difficult using traditional diagnostic approaches, which rely on pathogen detection that may not be immediately available or actionable in acute care settings.